• GSK Q1 2026 results call transcript detailed 5% sales growth to more than GBP 7.6 billion; management team included CEO Luke Miels, CFO Julie Brown, plus Nina Mojas, Deborah Waterhouse, Tony Wood, Julie Brown, Constantin Fest, with David Redfern joining Q&A.
• Management confirmed 2026 guidance; it flagged tougher vaccine comparators from Q2 as publicly funded Shingrix programs annualize in Japan and parts of Europe.
• Shingrix delivered record quarterly sales of more than GBP 1 billion, up 20%; US wholesaler inventory ended Q1 at 600,000 doses with retail inventory rising on pre-filled syringe rollout.
• Exdensur access remained limited ahead of expected US J-code timing in early July; management said about 70% of early starts came from switches off other biologics.
• GSK highlighted Phase III hepatitis B data for bepirovirsen; US PDUFA date set for Oct. 26 with Priority Review accepted in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.